Groups Similar Look up By Text Browse About

Similar articles
Article Id Title Prob Score Similar Compare
220972 ARSTECHNICA 2021-11-23:
Elizabeth Holmes throws scientists under the bus
1.000 Find similar Compare side-by-side
220826 THEVERGE 2021-11-23:
Elizabeth Holmes admitted to a key part of the case against her
0.979 0.539 Find similar Compare side-by-side
220635 ARSTECHNICA 2021-11-19:
Holmes claimed Theranos could do “more than 1,000 tests”—it did 12 var abtest_1814434 = new ABTest(1814434, 'click');
0.499 Find similar Compare side-by-side
220990 ARSTECHNICA 2021-11-24:
Elizabeth Holmes says she forged pharma reports—for all the right reasons
0.160 0.496 Find similar Compare side-by-side
220875 ARSTECHNICA 2021-11-22:
Wealth and privilege allowed Elizabeth Holmes to start Theranos
0.257 0.481 Find similar Compare side-by-side
220947 ARSTECHNICA 2021-11-23:
Are scientists less prone to motivated reasoning?
0.324 Find similar Compare side-by-side
220654 VENTUREBEAT 2021-11-19:
Apply now to speak at The Future of Work Summit — part of the VB Transform Technology Series
0.316 Find similar Compare side-by-side
221039 ZDNET 2021-11-22:
Morrison's pamphletocracy of critical tech holds barely a quantum of substance
0.313 Find similar Compare side-by-side
220838 VENTUREBEAT 2021-11-23:
The long-awaited evolution of learning labs to meet a cloud-centric world (VB Live)
0.304 Find similar Compare side-by-side
221038 ZDNET 2021-11-21:
Conglomerates are dead, but tech giants are conglomerates in training
0.298 Find similar Compare side-by-side
221137 THEVERGE 2021-11-24:
Pinterest settles lawsuit that alleged racial and gender discrimination
0.278 Find similar Compare side-by-side
220643 VENTUREBEAT 2021-11-19:
TruePlan brings data to companies’ headcount and hiring plans
0.276 Find similar Compare side-by-side
221012 VENTUREBEAT 2021-11-24:
Pryon Positions for Leadership in AI-Enhanced Knowledge Management With Funding and Talent Momentum
0.272 Find similar Compare side-by-side
220891 ARSTECHNICA 2021-11-22:
In a first, scientists captured growth of butterfly wings inside chrysalis on video
0.267 Find similar Compare side-by-side
220959 ARSTECHNICA 2021-11-23:
All three console makers now say they’re concerned about Activision
0.265 Find similar Compare side-by-side
221070 ZDNET 2021-11-23:
Bill Gates: Here are five books I loved reading this year
0.260 Find similar Compare side-by-side
221112 THEVERGE 2021-11-26:
Strange signals on Venus may be coming from an erupting volcano
0.258 Find similar Compare side-by-side
220646 VENTUREBEAT 2021-11-19:
Biopharma Industry Leaders Ian Read and Clive Meanwell Join Saama Board of Directors
0.257 Find similar Compare side-by-side
221154 ZDNET 2021-11-26:
From drones to virtual reality: How golf is now a favourite testing ground for new tech
0.255 Find similar Compare side-by-side
220999 VENTUREBEAT 2021-11-20:
3 tips for successful partnerships
0.250 Find similar Compare side-by-side
220904 VENTUREBEAT 2021-11-22:
Deliverr raises $250M to grow its ecommerce fulfillment network
0.249 Find similar Compare side-by-side
221111 ARSTECHNICA 2021-11-26:
Humans have broken a fundamental law of the ocean
0.248 Find similar Compare side-by-side
221021 TECHREPUBLIC 2021-11-22:
How to generate random letters in Excel
0.242 Find similar Compare side-by-side
220876 VENTUREBEAT 2021-11-21:
Report: Only 16% of orgs rank employee retention as top priority
0.239 Find similar Compare side-by-side
221062 ZDNET 2021-11-22:
David's wacky and wonderful holiday gift guide 2021
0.238 Find similar Compare side-by-side


ID: 220972


Date: 2021-11-23

Elizabeth Holmes throws scientists under the bus

Holmes' rosy view of Theranos technology was shaped by others, she claims. Elizabeth Holmes would like the jury to know that scientists, at Theranos and at other companies, led her astray. One of those scientists was Ian Gibbons, who led Theranos scientific research efforts. In 2008, he sent her a presentation about the companys latest technology, saying that the performance design goals have been demonstrated, that the results have been excellent, and that the companys technology was in clinical evaluation at several sites. Holmes told the court that she felt that meant the company was meeting its design goals, though she didnt define what those goals were. What did that slide mean, Downey asked Holmes. We had successfully achieved the objectives of the program, she said, an answer that neatly declines to specify those objectives. Were they to validate the technology? To receive the final payment on a contract? It wasnt clear. Weeks ago, the jury heard testimony from scientists at Pfizer and Schering-Plough, which was acquired by Merck, saying that neither company had validated Theranos technology. The jury also learned that the lack of validation didnt stop Holmes from sending investors a Theranos-authored report with those companies logos placed prominently at the top. In her testimony yesterday, Holmes maintained that she thought Schering-Plough, and later Merck, held positive views of Theranos technology based on a call with one of the companys scientists.   To support that notion, defense attorneys showed an email from Holmes assistant summarizing a 2010 call with Constance Cullen, the Schering-Plough scientist who had been tasked with reviewing Theranos technology. The assistant said that Cullen told Holmes to feel free to use her name when contacting other Merck scientists. All in all, it was awesome, I think, Holmes assistant wrote. Calling her every single morning for the last 3 weeks finally paid off… In previous testimony, Cullen said she was not impressed with Theranos technology and that she was swamped with work following Mercks acquisition of Schering-Plough. One interpretation of the 2010 call could be that an overworked Cullen was just trying to get a persistent Holmes off her back. In a moment of clarity, though, Holmes acknowledged that, while she had wanted to partner with the Department of Defense, Theranos never had a deal. Investors have testified that the company told them its devices were being used in the field by the military. But other parts of Holmes' testimony suggest that she viewed nearly every development with rose-colored glasses. Though Pfizer had not validated Theranos technology, Holmes held out hope that a Pfizer executives call for further interactions would lead to a concrete deal, not just more meetings. Holmes also said that she thought our system was working well after Gibbons sent her a report in 2008 that stated assay results have been precise. What neither Holmes nor her attorney discussed was that precise results do not always mean a system is working well. A precise assay returns results that are close to each other. An accurate assay reports the true value, or at least close to it. A good test is both accurate and precise. Theranos precise assay results may have been technically impressive — the machines were returning the same value, time and again — but it doesnt necessarily mean they were accurate. (Gibbons died by suicide in 2013 shortly before he was to give a deposition in a patent lawsuit involving Theranos.) Holmes apparently felt that this product roadmap was solid evidence of her companys technical capabilities, rather than a possible path to achieving them. I understood that the four series could do any blood test, she told the court. Holmes testimony continues today.